Clinical Challenges in Treating Cancer-Associated Thrombosis: A Clinically Oriented Review
Acta Haematologica · 2024
DOI: 10.1159/000542872 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Haematologica, 2024. Verfasst von Idan Goldberg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel. Hauptthemen laut MEDLINE: Anticoagulants, Brain Neoplasms, Neoplasms, Thrombosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background: Managing cancer-associated thrombosis (CAT) is a significant clinical challenge due to several factors such as increased bleeding tendency, frailty, and drug-drug interactions. For many years, the drug of choice for treating CAT was low molecular weight heparin (LMWH). Recently, direct oral anticoagulants (DOACs) entered to the therapeutic milieu of CAT. However, due to the large diversity among patients with CAT in clinical and laboratory characteristics, not all patients will equally benefit from treatment with DOACs. Furthermore, several subgroups of patients with CAT have specific characteristics that influence the anticoagulant decision-making process. Summary: In this review, we present four different theoretical clinical case scenarios, each representing a different challenge that is associated with thrombosis management; brain metastasis, malignancies of the gastrointestinal tract, drug-drug interactions (DDIs), and thrombocytopenia. By reviewing current literature, we suggest our clinical approach for managing these cases in the era of DOACs. Key Messages: (1) The management of patients with brain tumors and CAT is challenging due to increased risk for both intracranial hemorrhage and recurrent venous thromboembolism. Both LMWH and DOACs are optional treatment in this setting. (2) There are conflicting data regarding the bleeding risk in patients with GI malignancies. Treatment with LMWH should be considered specifically in patients with advanced disease and unresectable tumors. (3) There is a paucity of data regarding DDI in patients with CAT. However, caution should be exercised when prescribing DOACs to patients receiving concurrent medications that either affect DOAC metabolism or influence bleeding risk. (4) The management of patients with CAT and thrombocytopenia depends on the severity of thrombocytopenia and the timing of the thrombotic event.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Hematology, Davidoff Cancer Centre, Rabin Medical Centre, Petah Tikva, Israel.
- Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
- Department of Internal Medicine F - Recanati, Beilinson Hospital, Rabin Medical Centre, Petah Tikva, Israel.
- Departments of Internal Medicine and Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht Universiy Medical Center, Maastricht, The Netherlands.
- Thrombosis Expertise Center, Heart+ Vascular Center, Maastricht University Medical Center, Maastricht, The Netherlands.
- Center for Thrombosis and Hemostasis (CTH), Gutenberg University Medical Center, Mainz, Germany.
Förderung
- NCI NIH HHS
Zitieren
APA
Goldberg, I., Spectre, G., Raanani, P., Cate, H. T., & Leader, A. (2024). Clinical Challenges in Treating Cancer-Associated Thrombosis: A Clinically Oriented Review. Acta Haematologica. https://doi.org/10.1159/000542872
Vancouver
Goldberg I, Spectre G, Raanani P, Cate HT, Leader A. Clinical Challenges in Treating Cancer-Associated Thrombosis: A Clinically Oriented Review. Acta Haematologica. 2024. doi:10.1159/000542872
BibTeX
@article{Goldberg2024,
author = {Goldberg, Idan and Spectre, Galia and Raanani, Pia and Cate, Hugo Ten and Leader, Avi},
title = {Clinical Challenges in Treating Cancer-Associated Thrombosis: A Clinically Oriented Review},
journal = {Acta Haematologica},
year = {2024},
doi = {10.1159/000542872}
}
EUVIMED